A randomized, single-blind, three-part, phase III trial to investigate RDX-022 for the treatment of hyperkalaemia
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2017
At a glance
- Drugs RDX 7675 (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- 03 Jan 2017 Status changed from planning to recruiting, as per an Ardelyx media release.
- 09 May 2016 According to an Ardelyx media release, this trial is expected to initiate during the fourth quarter 2016.
- 09 May 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016, as per Ardelyx media release.